News
Journal of Medical Economics study shows significant cost savings via MAF Test® – guided adjuvant bisphosphonate therapyfor early-stage breast cancer
Inbiomotion, a company commercializing its proprietary MAF Test® for identifying high risk early-stage breast cancer patients, announces the publication of a landmark economic evaluation titled
INBRAIN Neuroelectronics Announces Collaboration to Advance Graphene-Based Brain-Computer Interfaces
INBRAIN Neuroelectronics has signed a know-how collaboration agreement with Mayo Clinic to accelerate the development and commercialization of its graphene-based brain-computer interface therapeutics (BCI-Tx). Business
Peptomyc Announces Leadership Transition to Support Next Phase of Growth
Barcelona, [July 2nd, 2025] — The Board of Directors of Peptomyc S.L., a pioneering biotech company developing innovative cancer therapies targeting the MYC oncoprotein, is pleased
deepull secures oversubscribed €50 million Series C financing to advance UllCORE diagnostic system for direct-from-blood rapid pathogen detection
deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced today the successful closing of an oversubscribed Series C financing round,
Accure Therapeutics awarded a total of $1.6M in grants from The Michael J. Fox Foundation and Fonds National de Recherche de Luxembourg to bring first-in-class drug for Parkinson’s disease to clinical trials
Accure Therapeutics, a private translational neuroscience R&D company, today announces its receipt of two grants totalling $1.6M for two separate development programs on its drug
Peptomyc announces Research IND Approval for Innovative Window of Opportunity Trial in Collaboration with OHSU Knight Cancer Institute, Portland, Oregon, USA, in PDAC patients
Peptomyc is pleased to announce the approval of a Research Investigational New Drug (IND) application for a groundbreaking Window of Opportunity trial in collaboration with
